​

TuHURA Biosciences Stock (NASDAQ:HURA)

OwnershipFinancialsChart
TuHURA Biosciences by TradingView

Previous Close

$2.08

52W Range

$0.41 - $3.90

50D Avg

$2.31

200D Avg

$1.88

Market Cap

$139.46M

Avg Vol (3M)

$863.65K

Beta

0.01

Div Yield

-

HURA Company Profile

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

19

IPO Date

Feb 22, 2013

Website

HURA Performance

HURA Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income-$-17.65M$-29.76M
Net Income$-30.06M$-21.68M$-29.32M
EBITDA-$-17.43M$-29.12M
Basic EPS$-0.63$-1.21$-11.29
Diluted EPS$-0.63$-1.21$-11.29

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
IRDOpus Genetics, Inc.
SPROSpero Therapeutics, Inc.
TVGNTevogen Bio Holdings Inc.
AGENAgenus Inc.
SEERSeer, Inc.
INOInovio Pharmaceuticals, Inc.
VTGNVistaGen Therapeutics, Inc.
CGTXCognition Therapeutics, Inc.
MCRBSeres Therapeutics, Inc.
ABOSAcumen Pharmaceuticals, Inc.